人脐血间充质干细胞静脉移植治疗失代偿期肝硬化的疗效观察  

作　　者：柯昌征[1] 刘莉[1] 李东[1] 陈悦[1] 孟忠吉[1] 

机构地区：[1]湖北医药学院附属太和医院感染科,442000

出　　处：《浙江临床医学》2014年第8期1185-1187,共3页Zhejiang Clinical Medical Journal

基　　金：湖北省科技计划研究与开发项目（医学临床研究中心2011BCB030）

摘　　要：目的：观察人脐带间充质干细胞静脉输注治疗失代偿期肝硬化的临床疗效及安全性。方法将65例失代偿期肝硬化患者随机分为两组，治疗组40例，对照组25例，对照组给予综合护肝、支持对症治疗，治疗组在对照组治疗基础上，通过外周静脉输注脐带血干细胞悬液100 ml，每周1次静脉输注，连续3次。分别观察两组治疗前及治疗后4周、8周、12周24周，患者的临床症状、肝功能、凝血功能、肝纤维化等指标变化。结果治疗组经人脐带间充质干细胞治疗后4周，白蛋白和凝血功能较治疗前明显改善，12周肝硬度值下降。临床症状和体征改善明显。结论外周静脉输注人脐带间充质干细胞治疗失代偿期肝硬化，近期可明显改善肝功能，提升白蛋白、改善凝血功能、改善肝纤维化程度等，可提高患者生存率。ObjectiveTo invstigate theclinic effects and safety of human Umbilical cord mesenchymal stem cells（UCMSCs） transplantation in treatment of patients with decompensated liver cirrhosis.Methods65 patients with decompensated liver cirrhosis were involved and divided into 2 groups.20 patients in the control group were treated with conventional therapy while 40 patients were received UCSCs transplantation via peripheraily venous based on conventional therapy,with 100 ml of UCSCs suspension once a week for 3 weeks.The clinical symptoms,serum ALT,Alb,Tbil,PT,and liver stifiness were determined before at week 0,4, 8,12,and 24 post the UCMSCs treatment.ResultsSerum markers of liver function and blood coagulation function before and after treatment of 40 cases were significantly different（P〈0.05）,liver fibrosis decline after 12 weeks.The differences in clinical symptoms and signs between the 2 groups were significant.ConclusionsThe transplantation of UC-MSCs via peripheraily vein is effective in short time for treatment of patients with decompensated liver cirrhosis.

关 键 词：脐带间充质干细胞 移植 失代偿期肝硬化 

分 类 号：R329.2[医药卫生—人体解剖和组织胚胎学]